Alivus Life Sciences FY26 Revenue Up 6.9%, Margins Expand

• Alivus Life Sciences reported FY26 revenue growth of 6.9% YoY to Rs. 25,518 Mn with EBITDA margins expanding 360 bps to 33.6%.
• PAT grew 16.2% YoY to Rs. 5,645 Mn while the company generated strong free cash flow of Rs. 2,590 Mn, maintaining a debt-free balance sheet.
• The company announced construction of a new R&D center in Taloja and provided FY27 guidance for high single-digit revenue growth with margins above 30%.